These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28579164)

  • 61. Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
    Izumi D; Miyahara M; Fujimoto N; Fukuoka S; Sakai M; Dohi K; Ito M
    Heart Vessels; 2016 Aug; 31(8):1247-56. PubMed ID: 26334709
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography.
    Tanigawa J; Barlis P; Dimopoulos K; Dalby M; Moore P; Di Mario C
    Int J Cardiol; 2009 May; 134(2):180-8. PubMed ID: 18775576
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term results of long segment coronary artery lesions overlapped with novolimus-eluting DESolve scaffold: Disappointment or futuristic?
    İbişoğlu E; Çakal S; Çakal B; Güneş HM; Boyraz B; Boztosun B
    Anatol J Cardiol; 2021 Dec; 25(12):912-919. PubMed ID: 34866586
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of lesion angle on optical coherence tomography findings and clinical outcomes after drug-eluting stent implantation in curved vessels.
    Nakamura S; Kimura S; Nakagama S; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hishikari K; Hikita H; Takahashi A; Hirao K
    Int J Cardiovasc Imaging; 2019 Dec; 35(12):2147-2155. PubMed ID: 31359232
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives.
    Nef HM; Wiebe J; Foin N; Blachutzik F; Dörr O; Toyloy S; Hamm CW
    Int J Cardiol; 2017 Jan; 227():127-133. PubMed ID: 27863289
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial.
    Lee SY; Kang DY; Hong SJ; Ahn JM; Ahn CM; Park DW; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Hong MK
    Circ Cardiovasc Interv; 2020 Jan; 13(1):e008383. PubMed ID: 32525410
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of neointimal coverage and extra-stent lumen between sirolimus and everolimus-eluting stent using optical coherence tomography.
    Oda T; Okamura T; Yamada J; Miyagi N; Uehara H; Nao T; Tateishi H; Maeda T; Nakamura T; Shiraishi K; Nakashima T; Nishimura S; Miura T; Matsuzaki M; Yano M
    Heart Vessels; 2016 Apr; 31(4):449-56. PubMed ID: 25614415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.
    Gil RJ; Bil J; Legutko J; Pawłowski T; Gil KE; Dudek D; Costa RA
    Int J Cardiovasc Imaging; 2018 Mar; 34(3):353-365. PubMed ID: 28965166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized comparison of stent strut coverage following angiography- or optical coherence tomography-guided percutaneous coronary intervention.
    Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Rev Esp Cardiol (Engl Ed); 2015 Mar; 68(3):190-7. PubMed ID: 25487222
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST.
    Guagliumi G; Capodanno D; Ikejima H; Bezerra HG; Sirbu V; Musumeci G; Fiocca L; Lortkipanidze N; Vassileva A; Tahara S; Valsecchi O; Costa MA
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):510-8. PubMed ID: 22431208
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H; Panoulas VF; Sato K; Miyazaki T; Naganuma T; Sticchi A; Figini F; Latib A; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Jun; 8(7):900-9. PubMed ID: 26003020
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) Xience V Study: use of the everolimus-eluting stent in saphenous vein graft lesions.
    Papayannis AC; Michael TT; Yangirova D; Abdel-Karim AR; Kohlhaas J; Mahmood A; Addo T; Haagen D; Makke L; Roesle M; Rangan B; Banerjee S; Brilakis ES
    J Invasive Cardiol; 2012 Aug; 24(8):390-4. PubMed ID: 22865309
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
    La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
    Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
    Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The DESolve
    Demola P; Meucci F; Stolcova M; Mario CD; Mattesini A
    Future Cardiol; 2021 Sep; 17(6):945-951. PubMed ID: 33507091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
    Cheng Y; Gasior P; Xia JG; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 Jul; 10(7):. PubMed ID: 28701488
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study.
    Takahara M; Kitahara H; Nishi T; Miura K; Miyayama T; Sugimoto K; Nakayama T; Fujimoto Y; Kobayashi Y
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):25-30. PubMed ID: 27601229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.
    Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547
    [TBL] [Abstract][Full Text] [Related]  

  • 80. DESolve novolimus-eluting bioresorbable coronary scaffold failure assessed by frequency-domain optical coherence tomography imaging.
    Porto I; Vergallo R; Sangiorgi GM; Burzotta F; Garbo R; D'Amario D; Trani C; Rebuzzi AG; Crea F
    Coron Artery Dis; 2016 Jun; 27(4):334-6. PubMed ID: 26882020
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.